Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Kivexa

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background: Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2012
2012
SummaryAbstractAbacavir and lamivudine (two nucleoside analogue reverse transcriptase inhibitors [NRTIs]), as separate… Expand
  • table I
  • table II
  • table III
  • figure 1
  • figure 2
2012
2012
Simplification of antiretroviral therapy (ART) may be an option for virologically suppressed patients for a variety of reasons… Expand
Highly Cited
2010
Highly Cited
2010
BACKGROUND Although antiretroviral therapy improves immune response, some human immunodeficiency virus-infected patients present… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
2010
2010
BACKGROUND Although efavirenz and lopinavir/ritonavir(r) are both recommended antiretroviral agents in antiretroviral-naïve HIV… Expand
  • table 1
  • figure 1
  • figure 4
  • figure 3
2010
2010
Check dietary supplement history before investigating apparently declining renal function 
Highly Cited
2008
Highly Cited
2008
Patients prefer fewer pills and once‐daily (qd) dosing without food restrictions. We assessed the impact on adherence [by… Expand
2008
2008
of results Between April 2006 and April 2008, 87 HAART-naive patients were commenced on either Truvada or Kivexa in combination… Expand
  • table 1
2008
2008
of results Of 139 patients, 81 were on Truvada and 58 on Kivexa. Most were black African (69%), mean age 38.1 (+/8.1) years and… Expand
  • table 1
2005
2005
Background:Abacavir (ABC) and lamivudine (3TC) administered twice daily were compared with an ABC + 3TC fixed-dose combination… Expand